EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Derin Karacabeyli iD, Diane Lacaille iD, Na Lu, Hui Xie iD, J Antonio Aviña-Zubieta iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Derin Karacabeyli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Autoimmune Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs or SGLT2i versus a weight‐neutral comparator (dipeptidyl peptidase 4 inhibitors [DPP4i]).

Methods

We performed a population‐based cohort study using administrative health data from a Canadian province with universal health care. We included adults with type 2 diabetes (T2D) and no prior ARD initiating a GLP‐1RA, SGLT2i, or DPP4i between January 1, 2014, and December 31, 2022. Incident ARD cases, including rheumatoid arthritis, psoriatic disease, axial spondyloarthritis, and systemic ARDs (SARDs; systemic lupus erythematosus, systemic sclerosis, Sjögren disease, idiopathic inflammatory myopathies, and systemic vasculitides), were identified using validated algorithms. Propensity score (PS) weighting was used to balance cohorts at treatment initiation. Then hazard ratios (HRs) were estimated using Cox regression.

Results

Among 229,300 adults, 49,514 initiated GLP‐1RAs, 101,925 initiated SGLT2i, and 77,861 initiated DPP4i. After PS weighting, ARD incidence per 10,000 person‐years was 29.1 (95% confidence interval [CI] 23.5–35.5) with GLP‐1RAs, 24.4 (95% CI 19.8–29.7) with SGLT2i, and 27.3 (95% CI 22.1–33.4) with DPP4i. Mean follow‐up was 1.3 to 1.6 years. Relative to DPP4i, adjusted HRs (aHRs) of ARD were 1.04 (95% CI 0.81–1.33) with GLP‐1RAs and 0.93 (95% CI 0.75–1.16) with SGLT2i. Risk of SARDs, but not other diseases, was lower with SGLT2i versus DPP4i (aHR 0.51 [95% CI 0.31–0.84]).

Conclusion

Neither GLP‐1RA nor SGLT2i treatment was associated with increased or decreased ARD risk versus DPP4i in adults with T2D; however, SGLT2i use was associated with significantly lower risk of SARDs, warranting further study. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsAutoimmune DiseasesRheumatic DiseasesDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansFemaleMaleMiddle AgedAgedAdultIncidenceCohort StudiesCanadaArthritis, Rheumatoid

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Experimental Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

ORCID-Profile: Derin Karacabeyli, Diane Lacaille, Hui Xie, J Antonio Aviña-Zubieta

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Karacabeyli, D., Lacaille, D., Lu, N., Xie, H., & Aviña-Zubieta, J. A. (2026). Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. Arthritis & Rheumatology. https://doi.org/10.1002/art.70044

Vancouver

Karacabeyli D, Lacaille D, Lu N, Xie H, Aviña-Zubieta JA. Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. Arthritis & Rheumatology. 2026. doi:10.1002/art.70044

BibTeX
@article{Karacabeyli2026,
  author = {Karacabeyli, Derin and Lacaille, Diane and Lu, Na and Xie, Hui and Aviña-Zubieta, J Antonio},
  title = {Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70044}
}
Kostenlos starten →